Literature DB >> 12473584

Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.

Eunice C Chan1, Shui Y Lam, Kenneth W Tsang, Bing Lam, James C M Ho, Kin H Fu, Wah K Lam, Yok L Kwong.   

Abstract

This study was aimed at defining patterns of aberrant gene methylation in non-small cell lung cancer (NSCLC) in Chinese patients and its use in detecting cancer cells in bronchoalveolar lavage (BAL). The methylation-specific PCR (MSP) was used to study methylation of the p16, retinoic acid receptor-beta (RARbeta), death-associated protein (DAP) kinase, and O(6)-methylguanine-DNA-methyltransferase (MGMT) genes in 75 NSCLCs [44 adenocarcinomas and 31 squamous cell carcinomas (SCCs)] and 68 BALs from suspected lung cancers. More females had adenocarcinoma than SCC (11 of 44 versus 2 of 31, P = 0.04). Aberrant methylation in at least one gene was found in 63 of 75 (84%) NSCLCs. p16, RARbeta, DAP kinase, and MGMT methylation was similar in adenocarcinoma and SCC. However, females with NSCLC showed more frequent p16 methylation than males (12 of 13 versus 36 of 62, P = 0.02), because of more frequent p16 methylation in female adenocarcinomas (10 of 11 versus 17 of 33, P = 0.02). This sexual difference was not observed in RARbeta, DAP kinase, and MGMT. At 92%, the frequency of p16 methylation in Chinese female NSCLC is one of the highest known. For BAL, MSP and cytological analysis showed concordant and discordant results in 25 of 68 and 43 of 68 samples. Of 41 MSP+/cytology- cases, 35 were eventually shown to have malignant lung lesions, 4 were at high risk but had no evidence of lung cancer, and 2 were lost to follow-up. There were two MSP-/cytology+ cases. Frequent gene methylations were seen in Chinese NSCLC patients. More frequent p16 methylation was seen in female patients. MSP is a useful molecular adjunct for cancer cell detection in BAL samples.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473584

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia.

Authors:  C S Chim; T K Fung; K F Wong; J S Lau; R Liang
Journal:  J Hum Genet       Date:  2006-08-03       Impact factor: 3.172

2.  Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa.

Authors:  Keizo Kato; Akira Hara; Toshiya Kuno; Hideki Mori; Tomomi Yamashita; Makoto Toida; Toshiyuki Shibata
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-22       Impact factor: 4.553

3.  Methylation of the RASSF1A and RARβ genes as a candidate biomarker for lung cancer.

Authors:  Wen Li; Jing Deng; Pei Jiang; Xiaoxi Zeng; Shunqin Hu; Jianxin Tang
Journal:  Exp Ther Med       Date:  2012-03-15       Impact factor: 2.447

Review 4.  Epigenetic diagnostics of cancer--the application of DNA methylation markers.

Authors:  Jaroslaw Paluszczak; Wanda Baer-Dubowska
Journal:  J Appl Genet       Date:  2006       Impact factor: 3.240

5.  Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma.

Authors:  Chor-Sang Chim; Raymond Liang; Tsz-Kin Fung; Chi-Lung Choi; Yok-Lam Kwong
Journal:  J Clin Pathol       Date:  2007-06       Impact factor: 3.411

6.  Detection of lung cancer using MAGE A1-6 and SSX4 RT-PCR expression profiles in the bronchial wash fluid.

Authors:  Kwan-Ho Lee; Kyung-Chul Shin; Chae-Hun Lee; Sang-Hoon Jheon; Chang-Ho Jeon
Journal:  Cancer Res Treat       Date:  2007-06-30       Impact factor: 4.679

7.  Aberrant gene promoter methylation in sputum from individuals exposed to smoky coal emissions.

Authors:  Yang Liu; Qing Lan; Min Shen; Jide Jin; Judy Mumford; Dianxu Ren; Phouthone Keohavong
Journal:  Anticancer Res       Date:  2008 Jul-Aug       Impact factor: 2.480

8.  SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates.

Authors:  Bernd Schmidt; Volker Liebenberg; Dimo Dietrich; Thomas Schlegel; Christoph Kneip; Anke Seegebarth; Nadja Flemming; Stefanie Seemann; Jürgen Distler; Jörn Lewin; Reimo Tetzner; Sabine Weickmann; Ulrike Wille; Triantafillos Liloglou; Olaide Raji; Martin Walshaw; Michael Fleischhacker; Christian Witt; John K Field
Journal:  BMC Cancer       Date:  2010-11-03       Impact factor: 4.430

Review 9.  A systematic review and meta-analysis: Association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma.

Authors:  Lin Chen; Yong Wang; Fen Liu; Liyao Xu; Feifei Peng; Ning Zhao; Biqi Fu; Zijie Zhu; Yu Shi; Jiansheng Liu; Renrui Wu; Chen Wang; Shengmin Yao; Yong Li
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

Review 10.  DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update.

Authors:  Paul P Anglim; Todd A Alonzo; Ite A Laird-Offringa
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.